The estimated Net Worth of Dwight H Egan is at least $740 Tisíc dollars as of 15 January 2021. Mr Egan owns over 50,000 units of Co-Diagnostics Inc stock worth over $63,000 and over the last 6 years he sold CODX stock worth over $0. In addition, he makes $676,875 as Chairman a CEO & Pres at Co-Diagnostics Inc.
Mr has made over 2 trades of the Co-Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of CODX stock worth $131,500 on 15 January 2021.
The largest trade he's ever made was exercising 150,000 units of Co-Diagnostics Inc stock on 20 November 2020 worth over $165,000. On average, Mr trades about 12,500 units every 4 days since 2018. As of 15 January 2021 he still owns at least 50,000 units of Co-Diagnostics Inc stock.
You can see the complete history of Mr Egan stock trades at the bottom of the page.
Dwight H. Egan is the Chairman, CEO & Pres at Co-Diagnostics Inc.
As the Chairman a CEO & Pres of Co-Diagnostics Inc, the total compensation of Mr Egan at Co-Diagnostics Inc is $676,875. There are no executives at Co-Diagnostics Inc getting paid more.
Mr Egan is 68, he's been the Chairman a CEO & Pres of Co-Diagnostics Inc since . There are 2 older and 7 younger executives at Co-Diagnostics Inc. The oldest executive at Co-Diagnostics Inc is Richard Serbin, 75, who is the Independent Director.
Dwight's mailing address filed with the SEC is 2401 S. FOOTHILL DRIVE SUITE D, , SALT LAKE CITY, UT, 84109.
Over the last 7 years, insiders at Co-Diagnostics Inc have traded over $2,459,090 worth of Co-Diagnostics Inc stock and bought 8,205 units worth $11,819,010 . The most active insiders traders include Reed L Benson, James B Nelson a Dwight H Egan. On average, Co-Diagnostics Inc executives and independent directors trade stock every 79 days with the average trade being worth of $38,652. The most recent stock trade was executed by Brian Lee Brown on 20 March 2023, trading 3,000 units of CODX stock currently worth $5,700.
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Co-Diagnostics Inc executives and other stock owners filed with the SEC include: